{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:39:21Z","timestamp":1794321561537,"version":"4.9.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1752-1947-8-417","type":"journal-article","created":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T10:01:17Z","timestamp":1418205677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report"],"prefix":"10.1186","volume":"8","author":[{"given":"Kazuo","family":"Ishizuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,10]]},"reference":[{"issue":"16","key":"3082_CR1","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353 (16): 1673-1684. 10.1056\/NEJMoa052122.","journal-title":"N Engl J Med"},{"issue":"16","key":"3082_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, L\u00e1ng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, R\u00fcschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353 (16): 1659-1672. 10.1056\/NEJMoa052306.","journal-title":"N Engl J Med"},{"issue":"3","key":"3082_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20 (3): 719-726. 10.1200\/JCO.20.3.719.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3082_CR4","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17 (9): 2639-2648.","journal-title":"J Clin Oncol"},{"key":"3082_CR5","first-page":"259","volume":"30","author":"S Masood","year":"2000","unstructured":"Masood S, Bui MM: Assessment of HER-2\/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci. 2000, 30: 259-265.","journal-title":"Ann Clin Lab Sci"},{"key":"3082_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987, 235: 177-182. 10.1126\/science.3798106.","journal-title":"Science"},{"key":"3082_CR7","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Ant\u00f3n A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005, 23: 4265-4274. 10.1200\/JCO.2005.04.173.","journal-title":"J Clin Oncol"},{"key":"3082_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"issue":"12","key":"3082_CR9","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/annonc\/mdm515","volume":"18","author":"A Mu\u00f1oz","year":"2007","unstructured":"Mu\u00f1oz A, Carrera S, Ferreiro J, de Lobera AR, Ma\u00f1\u00e9 JM, L\u00f3pez-Vivanco G: Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer. Ann Oncol. 2007, 18 (12): 2045-2046. 10.1093\/annonc\/mdm515.","journal-title":"Ann Oncol"},{"issue":"10","key":"3082_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1345\/aph.1L217","volume":"42","author":"S Srinivasan","year":"2008","unstructured":"Srinivasan S, Parsa V, Liu CY, Fontana JA: Trastuzumab-induced hepatotoxicity. Ann Pharmacother. 2008, 42 (10): 1497-1501. 10.1345\/aph.1L217.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"3082_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000346844","volume":"8","author":"D Vucicevic","year":"2013","unstructured":"Vucicevic D, Carey EJ, Karlin NJ: Trastuzumab-induced hepatotoxicity: a case report. Breast Care (Basel). 2013, 8 (2): 146-148.","journal-title":"Breast Care (Basel)"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-8-417\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T11:25:22Z","timestamp":1548156322000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-8-417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3082"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-8-417","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"14 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"417"}}